Brokerages Set Natera Inc (NTRA) Price Target at $29.00

Share on StockTwits

Natera Inc (NASDAQ:NTRA) has received an average recommendation of “Buy” from the eleven research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $29.00.

A number of analysts recently weighed in on NTRA shares. BidaskClub downgraded Natera from a “sell” rating to a “strong sell” rating in a report on Tuesday, November 13th. ValuEngine downgraded Natera from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 9th. Zacks Investment Research downgraded Natera from a “hold” rating to a “sell” rating in a report on Thursday, January 10th. Finally, Cowen restated a “buy” rating and issued a $30.00 price objective on shares of Natera in a report on Friday, November 9th.

Shares of NASDAQ:NTRA traded up $0.17 during trading on Friday, hitting $15.39. 5,512 shares of the company were exchanged, compared to its average volume of 617,966. The company has a market capitalization of $911.90 million, a PE ratio of -6.33 and a beta of 1.79. The company has a debt-to-equity ratio of 1.30, a quick ratio of 2.32 and a current ratio of 2.44. Natera has a 1-year low of $8.60 and a 1-year high of $29.62.

A number of hedge funds and other institutional investors have recently bought and sold shares of NTRA. FMR LLC acquired a new stake in Natera in the third quarter valued at $59,599,000. Jennison Associates LLC boosted its position in Natera by 39.1% during the third quarter. Jennison Associates LLC now owns 3,641,848 shares of the medical research company’s stock valued at $87,186,000 after acquiring an additional 1,024,225 shares during the last quarter. Vanguard Group Inc boosted its position in Natera by 28.9% during the third quarter. Vanguard Group Inc now owns 3,612,860 shares of the medical research company’s stock valued at $86,493,000 after acquiring an additional 808,976 shares during the last quarter. Vanguard Group Inc. boosted its position in Natera by 28.9% during the third quarter. Vanguard Group Inc. now owns 3,612,860 shares of the medical research company’s stock valued at $86,493,000 after acquiring an additional 808,976 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Natera by 92.9% during the third quarter. Renaissance Technologies LLC now owns 1,528,400 shares of the medical research company’s stock valued at $36,590,000 after acquiring an additional 736,000 shares during the last quarter. Institutional investors and hedge funds own 87.50% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: What is systematic risk?

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Jefferies Financial Group Analysts Cut Earnings Estimates for Lithia Motors Inc
Jefferies Financial Group Analysts Cut Earnings Estimates for Lithia Motors Inc
Peel Hunt Reaffirms Buy Rating for TBC Bank Group
Peel Hunt Reaffirms Buy Rating for TBC Bank Group
Barclays Cuts Shaftesbury  Price Target to GBX 910
Barclays Cuts Shaftesbury Price Target to GBX 910
Moneysupermarket.Com Group  PT Raised to GBX 325 at Barclays
Moneysupermarket.Com Group PT Raised to GBX 325 at Barclays
Novanta  Raised to “Buy” at Zacks Investment Research
Novanta Raised to “Buy” at Zacks Investment Research
Thomson Reuters  to Release Earnings on Tuesday
Thomson Reuters to Release Earnings on Tuesday


Leave a Reply

© 2006-2019 Ticker Report